Treating Heart Failure With hPSC-CMs

Prior treatment

• Patient received ICD transplantation, CRT or similar treatment.
• Patients with valvular heart disease or received heart valvular disease
• Patients received treatment of percutaneous transluminal coronary intervention (PCI)
• Patients previously suffered sustained ventricular tachycardia or sudden cardiac death.
• Recipients of organ transplant.
• On chronic therapy with immunosuppressant medication, such as glucocorticoid and TNFα antagonist.

Other illness

• Known, serious radiographic contrast allergy, penicillin allergy, streptomycin allergy.
• Clinical history of malignancy within 5 years (patients with prior malignancy must be disease free for 5 years).
• Non-cardiac condition that limits lifespan \<1 year.
• Patients allergy to or cannot use immunosuppressant.
• Other conditions that researchers consider not suitable to participate in this study.

Lab values

• Liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.
• Hematological abnormality: A hematocrit \<25% as determined by HCT, white blood cell\<2500/ul or platelet values \<100000/ul without another explanation.
• Coagulopathy (INR\>1.3) not due to a reversible cause.
• Serum positive for HIV, HBV, HCV, TP.

Other

• PRA ≥ 20% or DSA-positive.
• Patients with atrial fibrillation
• Baseline glomerular filtration rate \<30ml/min/1.73m2.
• Contra-indication to performance of a MRI scan.
• Currently enrolled other investigational therapeutic or device study.
• Patients who are pregnant or breast feeding.

• Aged 35-75 (including 35 and 75).
• Have signed the Informed Consent Form (ICF).
• Patients have chronic left ventricular dysfunction.
• Patients have NYHA Class III-IV cardiac function even after improved medication for the treatment of advanced chronic heart failure.
• Patients have indications for Coronary Artery Bypass Grafting.
• 20% ≤ LVEF ≤ 45% as determined by echocardiogram (data collected up to 6 months prior to inclusion evaluation are valid; data collected within 1 month since a myocardial infarction are invalid).
• Weakening or absence of segmental regional wall motion as determined by standard imaging.